<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031053</url>
  </required_header>
  <id_info>
    <org_study_id>ITRAPK</org_study_id>
    <nct_id>NCT04031053</nct_id>
  </id_info>
  <brief_title>Itraconazole Pharmacokinetic With and Without Efavirenz Using the Capsule Formulation as Part of Talaromycosis Treatment in HIV-infected Adults</brief_title>
  <acronym>ITRAPK</acronym>
  <official_title>Assessment of Itraconazole Pharmacokinetic With and Without Efavirenz Using the Capsule Formulation as Part of Talaromycosis Treatment in HIV-infected Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chiang Mai University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Thailand Research Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Chiang Mai University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Talaromycosis continues to be a common opportunistic fungal infection among people living&#xD;
      with HIV/AIDS (PLWHA) in Southeast Asia and remains a leading cause of death among this&#xD;
      population. Itraconazole (ITZ) is an important component of talaromycosis treatment. In&#xD;
      Thailand, the capsule formulation of ITZ is primarily used to treat talaromycosis but it is&#xD;
      known to have lower bioavailability than the more expensive solution formulation. Limited&#xD;
      data on the drug exposure of ITZ with the capsule formulation are available in adults PLWHA&#xD;
      in Thailand. Moreover, the effect of efavirenz (EFV), which has been recommended as the first&#xD;
      line antiretroviral therapy in Thailand, to ITZ level is not well understood. Thus, our aim&#xD;
      is to assess ITZ pharmacokinetics with and without EFV in adult PLWHA receiving talaromycosis&#xD;
      treatment with the capsule formulation. An understanding of the relationship between ITZ drug&#xD;
      exposure and its active metabolite (hydroxyl-itraconazole) and treatment response is also&#xD;
      planned to help optimize therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Enrolling by invitation</last_known_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Itraconazole and its metabolites level</measure>
    <time_frame>45 days</time_frame>
    <description>Itraconazole and its metabolite level will be measured to create drug level curve (before and after exposed to efavirenz)</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Pharmacokinetics</condition>
  <condition>Efavirenz</condition>
  <condition>Penicilliosis</condition>
  <arm_group>
    <arm_group_label>Intensive Pharmacokinetic Group</arm_group_label>
    <description>After receiving the first dose of ITZ, a single blood sample will be collected 12-hours post-dose. On Day 7, the blood will be collected for intensive PK study. After 7 days of combined ITZ + EFV, a blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. An identical set of intensive PK blood samples will be drawn 2 weeks after initiating the EFV based regimen.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trough Level Group</arm_group_label>
    <description>On Days 7 and 14, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose. After initiating an EFV based regimen, a single blood sample will be collected immediately (e.g. within 30 minutes) prior to administering the next ITZ dose on Days 7 and 14.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Pharmacokinetic study</intervention_name>
    <description>The blood will be collected at pre-dose and at 1, 3, 4, 5, 6, 8 and 12-hour post dose</description>
    <arm_group_label>Intensive Pharmacokinetic Group</arm_group_label>
    <arm_group_label>Trough Level Group</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      The plasma is stored for drug level analysis&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        HIV-infected participant who has an evidence of T. marneffei invasive infection will be&#xD;
        enrolled to the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18 years or older&#xD;
&#xD;
          2. Available documentation of HIV infection&#xD;
&#xD;
          3. ITZ capsule therapy is indicated for talaromycosis infection with the anticipation to&#xD;
             start on EFV-based ART&#xD;
&#xD;
          4. Willing to consent and compliance to the study protocol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of ITZ allergy&#xD;
&#xD;
          2. Pregnancy or lactation&#xD;
&#xD;
          3. Use concurrent medication that could interfere with ITZ level&#xD;
&#xD;
          4. Creatinine clearance less than 30 mL/min&#xD;
&#xD;
          5. Alanine aminotransferase (ALT) or Aspartate aminotransferase (AST) value is more than&#xD;
             5 times of upper normal limit and total bilirubin is more than 3 times above upper&#xD;
             normal limit&#xD;
&#xD;
          6. Hemoglobin less than 7 mg/dL&#xD;
&#xD;
          7. History of ITZ exposure within 35 days (only applicable to intense PK group)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Quanhathai Kaewpoowat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chiang Mai University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chiang Mai University Hospital</name>
      <address>
        <city>Chiang Mai</city>
        <zip>50200</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chiang Mai University</investigator_affiliation>
    <investigator_full_name>Quanhathai Kaewpoowat</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Efavirenz</keyword>
  <keyword>Penicilliosis</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

